

## CANADIAN CANCER TRIALS GROUP

## MELANOMA

DISEASE SITE COMMITTEE MEETING AGENDA

THE CHELSEA HOTEL, TORONTO, ONTARIO

ROOM: SCOTT

DATE: SUNDAY APRIL 30, 2017

TIME: 8:00 AM – 12:00 PM

CHAIRS: DR. TERESA PETRELLA, DR. ALAN SPATZ

(12:00 – 1:00 PM EXECUTIVE COMMITTEE MEETING – CLOSED)

8:00 - 8:10 am	<b>Welcome and Approval of 2016 Spring Meeting Minutes</b>	T. Petrella
8:10 - 8:40 am	<b>Results of CCSRI grant</b>	J. Dancey / T. Petrella
8:40 - 9:45 am	<b>Trial Updates</b>	
	<ul style="list-style-type: none"> <li>• MEC.3 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma (ECOG)</li> </ul>	T. Petrella
	<ul style="list-style-type: none"> <li>• MEC.4 – Randomized Phase II Study Comparing the Met Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma (Alliance)</li> </ul>	M. Butler
	<ul style="list-style-type: none"> <li>• MEC.5 – A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma (SWOG)</li> </ul>	T. Petrella
	<ul style="list-style-type: none"> <li>• IND224 – A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases</li> </ul>	T. Petrella
	<ul style="list-style-type: none"> <li>• IND225 – A Phase II Study of the Assessment of Response To Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker</li> </ul>	T. Petrella
	<ul style="list-style-type: none"> <li>• IND228 – A Phase II Study of Dervalumab and Tremelimumab in patients with advanced rare tumours</li> </ul>	J. Dancey
	<ul style="list-style-type: none"> <li>• ME13 – A Randomized Phase III Study of Duration of Anti-PD1 Therapy in Metastatic Melanoma (STOP-GAP)</li> </ul>	Tara Baetz/ Xinni Song
	<ul style="list-style-type: none"> <li>• PM1 – Canadian Profiling and Targeted agent Utilization tRial (CAPTUR). A phase II basket trial.</li> </ul>	J. Dancey

- 9:45 - 10:00 am     **Break**
- 10:00 - 11:00 am     **New Proposals**
- Prophylactic mesalamine to reduce immune-related AEs with combination ipilimumab / nivolumab in metastatic melanoma     J. Walker
  - Immune signature study     J. Walker
  - Intralesional IL-2 plus / minus Nivo for patients with stage IIIc,IVa melanoma     C. Giacomantonio
  - Avelumab in metastatic SCC     T. Petrella
  - S1616: Combining ipilimumab and nivolumab in advanced melanoma following progression on PD-1 inhibitor alone     T. Petrella
  - Imaging follow Up in advanced, non-metastatic melanoma     S. Latosinsky
- 11:00 - 12:00 pm     Genome Canada Grant     I. Watson/ A. Spatz
- 12:00 pm     **Meeting Adjourned**
- 12:00 - 1:00 pm     *Executive Committee meeting to follow (closed)*